Posted by Presse
Picture Gallery, Venture Capital
Wednesday, May 17th, 2017
Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials
Posted by Presse
Investment Services & Trading, Picture Gallery
Wednesday, October 17th, 2012
SAN FRANCISCO, CA — (Marketwire) — 10/17/12 — announced today that it has updated coverage on (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month target price of $3.50. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is developing two drugs: Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD) & OHR/AVR 118, in a Phase 2 trial, for the treatment of Cancer Cachexia. Therap